ERT acquisition of Exco InTouch to 'open up' BYOD market

By Melissa Fassbender

- Last updated on GMT

(Imag: iStock/Poike)
(Imag: iStock/Poike)

Related tags Exco intouch Health care provider Health care

The “Bring Your Own Device” (BYOD) continues to gain momentum with ERT’s acquisition of Exco InTouch, a provider of patient engagement, data capture, and digital health solutions.

ERT, a patient data collection solutions provider, announced the acquisition last week, explaining the combination delivers “end-to-end​” electronic clinical outcome assessments (eCOA​) patient engagement and digital health solutions.

James Corrigan, President and CEO, ERT, further commented in the company’s press release that acquisition joins the companies’ “science-driven solutions that are delivered across every modality with patient-driven solutions that open up the BYOD (Bring Your Own Device) marketto create a seamless approach to eCOA, patient engagement and digital health​.”

The BYOD approach allows patients to use their own smartphones to complete field-based PRO (patient reported outcomes) assessments. The approach has been gaining traction​ as an alternative to traditional models where phones are purchased for patients.

Tim Davis, Founder and CEO, Exco InTouch said ERT was “an obvious choice​” when assessing the company’s strategic business development​ options.

Now biopharmaceutical companies can turn to one company for all of their eCOA, patient engagement and commercialization needs, with confidence that their programs will have the right level of experience and expertise, anticipatory oversight, and adaptive problem solving required to ensure the most reliable results​," he added in the release.

Exco InTouch was also recently​ granted a US patent for its mobile health solutions.

As previously​ reported, the patent covers health and wellness programs delivering “condition-specific content and support to patients, healthcare professionals and other stakeholders in the healthcare industry​.”

ERT and Exco InTouch are not providing any additional comment at this time.

Financial terms of the transaction were not disclosed.

Related topics Markets & Regulations

Related news

Show more